Financhill
Sell
39

ENOV Quote, Financials, Valuation and Earnings

Last price:
$36.08
Seasonality move :
5.97%
Day range:
$35.39 - $36.17
52-week range:
$29.32 - $52.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.94x
P/B ratio:
0.79x
Volume:
531.5K
Avg. volume:
1.1M
1-year change:
-30.92%
Market cap:
$2.1B
Revenue:
$2.1B
EPS (TTM):
-$13.95

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ENOV
Enovis
$558.9M $0.74 5.83% 1731.46% $56.50
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -55.87% $13.8214
GMED
Globus Medical
$625.9M $0.74 16.49% 239.13% $84.00
ICUI
ICU Medical
$574.2M $1.28 -8.91% 316.67% $186.20
ITGR
Integer Holdings
$428.7M $1.24 6.46% 76.23% $147.88
XTNT
Xtant Medical Holdings
$31.2M -$0.01 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ENOV
Enovis
$36.06 $56.50 $2.1B -- $0.00 0% 0.94x
CATX
Perspective Therapeutics
$2.6300 $13.8214 $195.2M -- $0.00 0% 18.54x
GMED
Globus Medical
$61.25 $84.00 $8.3B 45.71x $0.00 0% 3.38x
ICUI
ICU Medical
$141.38 $186.20 $3.5B -- $0.00 0% 1.43x
ITGR
Integer Holdings
$120.99 $147.88 $4.2B 57.34x $0.00 0% 2.44x
XTNT
Xtant Medical Holdings
$0.66 $1.75 $92.3M -- $0.00 0% 0.74x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ENOV
Enovis
34.64% 1.134 63.52% 0.99x
CATX
Perspective Therapeutics
-- -1.032 -- --
GMED
Globus Medical
-- 2.870 -- 2.60x
ICUI
ICU Medical
43.6% 1.698 44.96% 0.90x
ITGR
Integer Holdings
43.46% 1.567 30% 1.99x
XTNT
Xtant Medical Holdings
43.24% -0.806 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ENOV
Enovis
$332.2M -$42.9M -18.51% -26.77% -8.62% -$44.9M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
GMED
Globus Medical
$402.7M $98.1M 4.22% 4.59% 16.4% $136.2M
ICUI
ICU Medical
$210.1M $29.6M -2.6% -4.64% 2.37% $34.5M
ITGR
Integer Holdings
$120.3M $55.8M 2.85% 4.85% -0.02% $6.1M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

Enovis vs. Competitors

  • Which has Higher Returns ENOV or CATX?

    Perspective Therapeutics has a net margin of -10.02% compared to Enovis's net margin of --. Enovis's return on equity of -26.77% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    59.45% -$0.98 $4B
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About ENOV or CATX?

    Enovis has a consensus price target of $56.50, signalling upside risk potential of 56.68%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 430.96%. Given that Perspective Therapeutics has higher upside potential than Enovis, analysts believe Perspective Therapeutics is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is ENOV or CATX More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock ENOV or CATX?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or CATX?

    Enovis quarterly revenues are $558.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Enovis's net income of -$56M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Enovis's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.94x versus 18.54x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.94x -- $558.8M -$56M
    CATX
    Perspective Therapeutics
    18.54x -- -- -$18.2M
  • Which has Higher Returns ENOV or GMED?

    Globus Medical has a net margin of -10.02% compared to Enovis's net margin of 12.62%. Enovis's return on equity of -26.77% beat Globus Medical's return on equity of 4.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    59.45% -$0.98 $4B
    GMED
    Globus Medical
    67.33% $0.54 $4.1B
  • What do Analysts Say About ENOV or GMED?

    Enovis has a consensus price target of $56.50, signalling upside risk potential of 56.68%. On the other hand Globus Medical has an analysts' consensus of $84.00 which suggests that it could grow by 37.14%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    GMED
    Globus Medical
    5 5 0
  • Is ENOV or GMED More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

  • Which is a Better Dividend Stock ENOV or GMED?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or GMED?

    Enovis quarterly revenues are $558.8M, which are smaller than Globus Medical quarterly revenues of $598.1M. Enovis's net income of -$56M is lower than Globus Medical's net income of $75.5M. Notably, Enovis's price-to-earnings ratio is -- while Globus Medical's PE ratio is 45.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.94x versus 3.38x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.94x -- $558.8M -$56M
    GMED
    Globus Medical
    3.38x 45.71x $598.1M $75.5M
  • Which has Higher Returns ENOV or ICUI?

    ICU Medical has a net margin of -10.02% compared to Enovis's net margin of -2.56%. Enovis's return on equity of -26.77% beat ICU Medical's return on equity of -4.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    59.45% -$0.98 $4B
    ICUI
    ICU Medical
    34.75% -$0.63 $3.5B
  • What do Analysts Say About ENOV or ICUI?

    Enovis has a consensus price target of $56.50, signalling upside risk potential of 56.68%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 31.7%. Given that Enovis has higher upside potential than ICU Medical, analysts believe Enovis is more attractive than ICU Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    ICUI
    ICU Medical
    3 1 0
  • Is ENOV or ICUI More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

  • Which is a Better Dividend Stock ENOV or ICUI?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or ICUI?

    Enovis quarterly revenues are $558.8M, which are smaller than ICU Medical quarterly revenues of $604.7M. Enovis's net income of -$56M is lower than ICU Medical's net income of -$15.5M. Notably, Enovis's price-to-earnings ratio is -- while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.94x versus 1.43x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.94x -- $558.8M -$56M
    ICUI
    ICU Medical
    1.43x -- $604.7M -$15.5M
  • Which has Higher Returns ENOV or ITGR?

    Integer Holdings has a net margin of -10.02% compared to Enovis's net margin of -5.14%. Enovis's return on equity of -26.77% beat Integer Holdings's return on equity of 4.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    59.45% -$0.98 $4B
    ITGR
    Integer Holdings
    27.51% -$0.66 $2.8B
  • What do Analysts Say About ENOV or ITGR?

    Enovis has a consensus price target of $56.50, signalling upside risk potential of 56.68%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 22.22%. Given that Enovis has higher upside potential than Integer Holdings, analysts believe Enovis is more attractive than Integer Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    ITGR
    Integer Holdings
    6 2 0
  • Is ENOV or ITGR More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

  • Which is a Better Dividend Stock ENOV or ITGR?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or ITGR?

    Enovis quarterly revenues are $558.8M, which are larger than Integer Holdings quarterly revenues of $437.4M. Enovis's net income of -$56M is lower than Integer Holdings's net income of -$22.5M. Notably, Enovis's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 57.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.94x versus 2.44x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.94x -- $558.8M -$56M
    ITGR
    Integer Holdings
    2.44x 57.34x $437.4M -$22.5M
  • Which has Higher Returns ENOV or XTNT?

    Xtant Medical Holdings has a net margin of -10.02% compared to Enovis's net margin of 0.18%. Enovis's return on equity of -26.77% beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    59.45% -$0.98 $4B
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About ENOV or XTNT?

    Enovis has a consensus price target of $56.50, signalling upside risk potential of 56.68%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 164.19%. Given that Xtant Medical Holdings has higher upside potential than Enovis, analysts believe Xtant Medical Holdings is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is ENOV or XTNT More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock ENOV or XTNT?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or XTNT?

    Enovis quarterly revenues are $558.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Enovis's net income of -$56M is lower than Xtant Medical Holdings's net income of $58K. Notably, Enovis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.94x versus 0.74x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.94x -- $558.8M -$56M
    XTNT
    Xtant Medical Holdings
    0.74x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

How to Change Your Stock Portfolio During a Bear Market
How to Change Your Stock Portfolio During a Bear Market

The standard definition of a bear market is that one…

Why Is Newegg Commerce Up So Much?
Why Is Newegg Commerce Up So Much?

Consumer electronics eCommerce store Newegg (NASDAQ:NEGG) has staged a dramatic…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
81
SMLR alert for May 17

Semler Scientific [SMLR] is up 28.56% over the past day.

Sell
25
GLOB alert for May 17

Globant SA [GLOB] is down 23.54% over the past day.

Buy
94
HIMS alert for May 17

Hims & Hers Health [HIMS] is up 10.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock